- Home
- MGTX vs ANAB Comparison
MGTX vs ANAB Comparison
Compare MGTX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- ANAB
- Stock Information
- Founded
- MGTX 2015
- ANAB 2005
- Country
- MGTX United States
- ANAB United States
- Employees
- MGTX N/A
- ANAB N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- ANAB Health Care
- Exchange
- MGTX Nasdaq
- ANAB Nasdaq
- Market Cap
- MGTX 670.2M
- ANAB 630.2M
- IPO Year
- MGTX N/A
- ANAB 2017
- Fundamental
- Price
- MGTX $7.99
- ANAB $21.08
- Analyst Decision
- MGTX Strong Buy
- ANAB Buy
- Analyst Count
- MGTX 2
- ANAB 10
- Target Price
- MGTX $24.00
- ANAB $48.00
- AVG Volume (30 Days)
- MGTX 291.9K
- ANAB 515.2K
- Earning Date
- MGTX 11-12-2025
- ANAB 11-04-2025
- Dividend Yield
- MGTX N/A
- ANAB N/A
- EPS Growth
- MGTX N/A
- ANAB N/A
- EPS
- MGTX N/A
- ANAB N/A
- Revenue
- MGTX $37,917,000.00
- ANAB $123,164,000.00
- Revenue This Year
- MGTX $145.67
- ANAB $11.40
- Revenue Next Year
- MGTX $167.61
- ANAB $8.17
- P/E Ratio
- MGTX N/A
- ANAB N/A
- Revenue Growth
- MGTX 366.84
- ANAB 304.17
- 52 Week Low
- MGTX $3.94
- ANAB $12.21
- 52 Week High
- MGTX $8.98
- ANAB $39.50
- Technical
- Relative Strength Index (RSI)
- MGTX 58.18
- ANAB 47.97
- Support Level
- MGTX $7.21
- ANAB $17.11
- Resistance Level
- MGTX $7.91
- ANAB $24.07
- Average True Range (ATR)
- MGTX 0.38
- ANAB 1.49
- MACD
- MGTX 0.03
- ANAB -0.03
- Stochastic Oscillator
- MGTX 92.82
- ANAB 57.03
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).